KKRC
JAZZ icon

Kohlberg Kravis Roberts & Co’s Jazz Pharmaceuticals JAZZ Stock Holding History

Kohlberg Kravis Roberts & Co’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-3,185,058
Closed -$403M – 151
2013
Q4 		$403M Hold
3,185,058
– – 6.78% 5
2013
Q3 		$293M Hold
3,185,058
– – 5.53% 5
2013
Q2 		$219M Buy
+3,185,058
New +$195M 4.32% 6

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.62B AUM 39.13% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Kohlberg Kravis Roberts & Co's JAZZ Position: Q1 2014 in Review

Kohlberg Kravis Roberts & Co sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2014, closing a stake of 3,185,058 shares — an estimated $403M sold.

Kohlberg Kravis Roberts & Co first reported a position in JAZZ in Q2 2013 and held it in 3 quarters. The position peaked at $403M in Q4 2013. 318 funds tracked by Wall St. Rank hold JAZZ as of Q1 2014.

  • Kohlberg Kravis Roberts & Co reported no remaining Jazz Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Kohlberg Kravis Roberts & Co sold 3,185,058 Jazz Pharmaceuticals shares in Q1 2014, an estimated $403M.
  • Kohlberg Kravis Roberts & Co first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Kohlberg Kravis Roberts & Co's Jazz Pharmaceuticals position peaked at $403M in Q4 2013.
  • 318 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2014.

Based on Kohlberg Kravis Roberts & Co's 13F filing for Q1 2014, filed 15 May 2014.